{
  "asOf": "2026-10-29",
  "window": {
    "start": "2025-10-29",
    "end": "2026-10-29"
  },
  "method": "Targeted original-source expansion plus ten-query, fully paginated ClinicalTrials.gov keyword retrieval with record-level screening. Registry results are a scoped search corpus, not a global or verified trials census. Qualified clinical/legal and independent authenticity review remain outstanding. Earlier corpus has not been wholly re-audited. Clinical expansion adds original abstract and sponsor-release analyses of three randomized phase 3 studies plus a product-specific FDA approval revision; these are not a global trial or annual-news census.",
  "documents": [
    {
      "url": "https://www.fda.gov/media/193342/download",
      "reviewed": "Full eight-page briefing introduction; scope, stages, nominations and staff proposals. No committee votes established."
    },
    {
      "url": "https://www.fda.gov/media/193773/download",
      "reviewed": "Relevant passages on PDF pages 54–55, 82–83, 98, 101, 105, 110–112 and proposal pages. Not a full assessment of all 149 pages."
    },
    {
      "url": "https://pubmed.ncbi.nlm.nih.gov/42885452/",
      "reviewed": "Complete PubMed abstract and publication metadata, not the journal full text. Review search cutoff June 1, 2026."
    },
    {
      "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026",
      "reviewed": "FDA excerpts covering products, intended-use reasoning including footnote 1, date and response requirement. Later response/closeout not verified."
    },
    {
      "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/royal-peptides-llc-734884-08242026",
      "reviewed": "FDA excerpts covering products, issue/content dates and response requirement. Later response/closeout not verified."
    },
    {
      "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wholesale-peptide-729447-06172026",
      "reviewed": "FDA excerpts covering products, issue/content dates, disclaimer and response requirement. Later response/closeout not verified."
    },
    {
      "url": "https://clinicaltrials.gov/api/v2/studies",
      "reviewed": "Ten explicit queries, all returned pages; 44 deduplicated records retained with query log. Title/summary/intervention screening for all; highlighted full descriptions/design fields inspected. Separate source and screening JSON, hash-bound to prevent silent refresh promotion."
    },
    {
      "url": "https://clinicaltrials.gov/study/NCT07487363",
      "reviewed": "Full retrieved brief and detailed description explicitly identify fictional/example study; status nevertheless recruiting. Excluded from actual clinical-testing evidence; no allegation about creator intent."
    },
    {
      "url": "https://clinicaltrials.gov/study/NCT07481734",
      "reviewed": "Title explicitly says Mock Study and description says mock protocol. Excluded from actual clinical-testing evidence."
    },
    {
      "url": "https://clinicaltrials.gov/study/NCT07803250",
      "reviewed": "Registry summary, structured enrollment, status, dates, arms, intervention labels and primary outcome reviewed. 30-versus-twenty and saline-versus-no-treatment conflicts preserved; no independent university or regulatory-file confirmation."
    },
    {
      "url": "https://clinicaltrials.gov/study/NCT07752381",
      "reviewed": "Registry source fields show first posting after recorded conduct, 40 actual enrollment, commercial product, no results module. No inference about unsearched publications or regulatory classification."
    },
    {
      "url": "https://www.accessdata.fda.gov/Scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316",
      "reviewed": "Original 22 December 2025 approval action, tablet route and later label-action history. Not a review of every full label revision."
    },
    {
      "url": "https://clinicaltrials.gov/about-site/about-ctg",
      "reviewed": "Agency explanation of sponsor/investigator responsibility and limited government review; no registry-listing approval inferred."
    },
    {
      "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2604169",
      "reviewed": "Complete TRIUMPH-1 abstract and publication record, not full text/protocol/supplements. Weight treatment-regimen values; subgroup estimand distinctions and Lilly funding."
    },
    {
      "url": "https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",
      "reviewed": "Targeted trial design, 80-week efficacy-estimand headline, 104-week selected extension criteria and estimand footnotes. Not a comprehensive safety review."
    },
    {
      "url": "https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html",
      "reviewed": "Original distributed Lilly release: complete trial-specific GI and adverse-event discontinuation passages. Unrelated Zepbound/Foundayo safety sections not attributed to retatrutide."
    },
    {
      "url": "https://www.sec.gov/Archives/edgar/data/353278/000117184326000996/f6k_022326.htm",
      "reviewed": "REDEFINE 4 original sponsor filing: 809 randomized, open-label 84-week design, both estimand values, missed non-inferiority and qualitative safety paragraph. Full protocol and formal margin/CI not reviewed."
    },
    {
      "url": "https://pubmed.ncbi.nlm.nih.gov/42251859/",
      "reviewed": "Complete REIMAGINE 2 abstract and metadata; original NCBI BioC abstract retrieved separately. HbA1c primary endpoint, CI, denominator and any-adverse-event rates. Full paper/supplements not reviewed."
    },
    {
      "url": "https://www.novonordisk-us.com/media/press-releases/cagrisema-phase3-reimagine-t2d-ada-2026.html",
      "reviewed": "REIMAGINE 2 efficacy-estimand weight table, population and investigational status from same-day sponsor release, not independent full-paper extraction."
    },
    {
      "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide",
      "reviewed": "Complete approval announcement, indication, higher-dose skin-sensation signal and boxed-warning summary. Full label and pivotal-trial reports not reviewed."
    }
  ],
  "excludedLead": {
    "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pinnacle-professional-research-dba-pinnacle-peptides-719337-12122025",
    "reason": "Letter reviewed; named products are SARMs. Company name containing Peptides does not make this a peptide-specific clinical event. Retained as taxonomy lesson, not added to peptide-event count."
  },
  "remaining": [
    "Systematic month-by-month news-archive review and broader trial-register coverage with reproducible inclusion/exclusion logs; ten named ClinicalTrials.gov term searches are now documented separately",
    "PCAC original minutes/transcript and vote outcomes",
    "Independent validation and full-paper/results review of non-GLP-1 trial leads; ten-query ClinicalTrials.gov retrieval is complete only for its stated terms, not global registries or all synonyms",
    "Court outcomes and post-letter response/closeout checks",
    "Provider entity/licensure/service taxonomy validation; social authorized feeds and reliable engagement samples; app-store census and traction",
    "Full-paper/protocol/supplement extraction for TRIUMPH-1 and REIMAGINE 2; complete peer-reviewed REDEFINE 4 results, margin and safety appraisal; current labels and qualified review before clinical use"
  ],
  "registrySnapshot": {
    "url": "/trial-registry-snapshot.json",
    "screening": "/trial-registry-screening.json",
    "queries": 10,
    "deduplicatedReturns": 44,
    "firstPostedInAnnualWindow": 13,
    "meaning": "Search-return counts, not verified human peptide-treatment trials or confirmed trial launches."
  },
  "corpus": {
    "reportingRecords": 40,
    "datedRecords": 39,
    "synthesisRecords": 1,
    "monthly": {
      "2025-10": 1,
      "2025-11": 2,
      "2025-12": 1,
      "2026-01": 2,
      "2026-02": 3,
      "2026-03": 4,
      "2026-04": 3,
      "2026-05": 1,
      "2026-06": 3,
      "2026-07": 2,
      "2026-08": 4,
      "2026-09": 5,
      "2026-10": 8
    },
    "categories": {
      "Clinical": 9,
      "Evidence": 3,
      "Market": 6,
      "Policy": 17,
      "Safety": 4
    },
    "meaning": "Counts describe this corpus, not complete industry activity."
  }
}